VILLANELLE LIFE

VILLANELLE LIFE is committed to building an AI-assisted diagnostics and drug platform for unmet needs. Guided by precision medicine, the company has developed an AI-based new drug target discovery platform. Leveraging clinical samples from real patients collected from over 20 Class III, Grade A hospitals, combined with exclusive AI algorithms and bioinformatics analysis technologies, the company has established a unique integrated precision medicine platform. This platform spans upstream target and biomarker discovery to downstream drug and auxiliary diagnostic development, addressing the long-standing and urgent clinical needs of complex diseases (such as cancer, acute and critical illnesses, cardiovascular diseases, etc.) in early screening, diagnosis, progression management, and treatment.